Literature DB >> 20494582

Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold.

Mauro Gobbini1, Silvia Armaroli, Leonardo Banfi, Alessandra Benicchio, Giulio Carzana, Patrizia Ferrari, Giuseppe Giacalone, Giuseppe Marazzi, Barbara Moro, Rosella Micheletti, Simona Sputore, Marco Torri, Maria Pia Zappavigna, Alberto Cerri.   

Abstract

We report the synthesis and biological properties of novel analogues of Istaroxime acting as positive inotropic compounds through the inhibition of the Na(+),K(+)-ATPase. We explored the chemical space around the position 6 of the steroidal scaffold by changing the functional groups at that position and maintaining a basic oximic chain in position 3. Some compounds showed inhibitory potencies of the Na(+),K(+)-ATPase higher than Istaroxime and many of the compounds tested in vivo were safer than digoxin, the classic digitalis compound currently used for the treatment of congestive heart failure as inotropic agent. The 3D-QSAR analyses using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) methods have been successfully applied to a set of 63 androstane derivatives as Na(+),K(+)-ATPase inhibitors. The contour plots provide many useful insights into relationships between structural features and inhibitory potency. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494582     DOI: 10.1016/j.bmc.2010.04.095

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure.

Authors:  Andrea Luraghi; Mara Ferrandi; Paolo Barassi; Martina Arici; Shih-Che Hsu; Eleonora Torre; Carlotta Ronchi; Alessio Romerio; Gwo-Jyh Chang; Patrizia Ferrari; Giuseppe Bianchi; Antonio Zaza; Marcella Rocchetti; Francesco Peri
Journal:  J Med Chem       Date:  2022-05-17       Impact factor: 8.039

2.  Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy.

Authors:  S M Kamel; C J M van Opbergen; C D Koopman; A O Verkerk; B J D Boukens; B de Jonge; Y L Onderwater; E van Alebeek; S Chocron; C Polidoro Pontalti; W J Weuring; M A Vos; T P de Boer; T A B van Veen; J Bakkers
Journal:  Nat Commun       Date:  2021-12-09       Impact factor: 14.919

Review 3.  Na+/K+-ATPase Revisited: On Its Mechanism of Action, Role in Cancer, and Activity Modulation.

Authors:  Jiří Bejček; Vojtěch Spiwok; Eva Kmoníčková; Silvie Rimpelová
Journal:  Molecules       Date:  2021-03-28       Impact factor: 4.411

4.  Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.

Authors:  Konstantinos Alevizopoulos; Konstantinos Dimas; Natalia Papadopoulou; Eva-Maria Schmidt; Anna Tsapara; Saad Alkahtani; Sabina Honisch; Kyriakos C Prousis; Saud Alarifi; Theodora Calogeropoulou; Florian Lang; Christos Stournaras
Journal:  Oncotarget       Date:  2016-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.